Physician profile
Peter O Lutz
NPI 1700815891
$63,428.60
in general payments reported to CMS, 2019-2025
56 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,074 · 2020: $3,976 · 2021: $1,934 · 2022: $6,000 · 2023: $16K · 2024: $23K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Food and Beverage: $10K · Travel and Lodging: $6,071 · Education: $6,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,270.62 |
| Food and Beverage | $10,103.38 |
| Travel and Lodging | $6,071.13 |
| Education | $6,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $18,619.73 | 2019-2025 | Monarch Platform |
| Medical Device Business Services, INC. | $14,303.40 | 2022-2025 | Monarch Platform, Monarch |
| Intuitive Surgical, INC. | $8,190.00 | 2022-2023 | Da Vinci Surgical System |
| Fujifilm Healthcare Americas Corporation | $7,522.40 | 2020-2025 | Fujifilm |
| Glaxosmithkline, LLC. | $2,642.58 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,803.39 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,530.59 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $984.98 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $766.18 | 2019-2024 | Prolastin-C Liquid, Xembify |
| Genentech USA, INC. | $636.95 | 2019-2025 | Xolair, Polivy |
| Takeda Pharmaceuticals U.S.A., INC. | $607.08 | 2021-2025 | Cuvitru, Hyqvia, Glassia |
| Insmed, INC. | $565.98 | 2019-2025 | Arikayce, Brinsupri |
| Novartis Pharmaceuticals Corporation | $525.07 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $486.97 | 2019-2025 | Opsumit, Opsynvi |
| Electromed, INC. | $452.32 | 2019-2025 | Smartvest |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $447.37 | 2020-2024 | Acthar |
| Genzyme Corporation | $306.32 | 2019-2025 | |
| Noah Medical Corporation | $302.25 | 2024 | Galaxy |
| United Therapeutics Corporation | $223.66 | 2020-2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $202.21 | 2019-2025 | Dificid, Recarbrio, Zerbaxa |
| Verona Pharma, INC. | $190.59 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $169.08 | 2019-2024 | Yupelri |
| Philips North America LLC | $148.06 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Pulmonx Corporation | $145.58 | 2021-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Optinose US, INC. | $141.95 | 2019-2024 | |
| Eisai INC. | $126.06 | 2022-2024 | |
| Blueprint Medicines Corporation | $125.14 | 2023-2024 | Ayvakit |
| Ani Pharmaceuticals, INC. | $110.92 | 2022-2024 | Purified Cortrophin Gel |
| Amgen INC. | $106.82 | 2021-2025 | Tezspire, Tavneos |
| Olympus America INC. | $91.01 | 2025 | Spiration Valve System |
| Body Vision Medical INC. | $80.88 | 2023 | Lungvision |
| Mallinckrodt Enterprises LLC | $73.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $65.88 | 2019-2022 | |
| Incyte Corporation | $63.59 | 2022-2025 | Opzelura, Pemazyre, Monjuvi |
| Biocryst US Sales Co., LLC | $57.30 | 2024-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $57.05 | 2025 | Neffy |
| Gilead Sciences, INC. | $52.33 | 2019-2021 | |
| Baxter Healthcare | $50.91 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Bayer Healthcare Pharmaceuticals INC. | $50.90 | 2021-2024 | |
| Vifor Pharma, INC. | $47.60 | 2024 | Zemaira |
| Viatris Specialty LLC | $46.91 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $39.27 | 2022 | |
| Shire North American Group INC | $33.23 | 2019 | |
| Circassia INC. | $30.72 | 2019 | |
| Abbvie INC. | $27.75 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $23.42 | 2021 | |
| Pfizer INC. | $18.68 | 2024 | |
| Mayne Pharma Commercial LLC | $18.22 | 2022 | |
| Csl Behring | $18.18 | 2023 | Haegarda |
| Advanced Respiratory, INC | $15.72 | 2021 | |
| Rigel Pharmaceuticals, INC. | $15.60 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.50 | 2021 | |
| Genmab U.S., INC. | $15.28 | 2024 | Epkinly |
| Emd Serono, INC. | $15.24 | 2025 | |
| Hikma Pharmaceuticals USA | $12.81 | 2023 | Ryaltris |
| Inogen, INC. | $7.97 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lutz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.